News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Capricor Therapeutics, Inc. To Present On Exosomes As A Basis For Innovative Platform Technology At 11th International Symposium On Stem Cell Therapy And Cardiovascular Innovations


5/29/2014 9:29:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES, May 28, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it will present findings from a preclinical study on exosomes, Capricor's newly licensed platform technology, at the 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations, being held May 29-30, 2014 in Madrid, Spain. The preclinical study sponsored by Cedars-Sinai Medical Center showed that exosomes were able to improve cardiac function and reduce the damage resulting from a heart attack.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES